Lasker Award recipient had retracted some of his work — a sign of strength, not sloppiness
While retractions are usually seen as black marks on a career, a signal of sloppy or dishonest research, sometimes the opposite is true.
Axel Ullrich, who directs the department of molecular biology at the Max Planck Institute of Biochemistry, shared a stake in this year’s $250,000 Lasker Award for his work on Herceptin, a treatment for breast cancer. Ullrich’s Lasker-DeBakey Clinical Medical Research Award, announced last week, will join a slew of coveted honors in biomedicine that already sit on his mantel, including the King Faisal Prize, the Warren Alpert Foundation Prize, the Wolf Prize and others.
The Lasker
